缺血性卒中领域孟德尔随机化研究的文献计量学与可视化分析

doi:10.3969/j.issn.1673－5765.2023.03.006

摘要/Abstract

摘要： 目的探讨缺血性卒中领域孟德尔随机化研究的现状及热点，为该领域未来研究方向、药物靶点挖掘方向和探索机制提供参考。
方法在Web of Science核心合集中检索截至2022年9月应用孟德尔随机化研究缺血性卒中的相关英文文献，用CiteSpace进行发表文献的合作网络分析（国家、机构、学者）、文献共被引情况分析、关键词共现和聚类分析。利用PharmSnap全球新药数据库查询经孟德尔随机化确定与缺血性卒中具有因果关系的生物标志物的药物研发情况。
结果检索到文献200篇，相关研究2018年进入快速发展阶段。英国发文量为80篇、中介中心性为0.37、存在合作的国家有27个，美国发文量为63篇、中介中心性为0.10、存在合作的国家有21个，以上数据均位列所有国家的前3位，使英国和美国成为研究中心；中国发文量达到106篇，但仅与16个国家存在合作，相对较少；德国学者Rainer Malik发文20篇、文献共被引次数552次、合作学者25人，均位列第一。关键词聚类图中，IL-6是关键词聚类图中唯一被定义为聚类标签的生物因子，且炎症因素是关键词共现图中近3年研究第二多的缺血性卒中风险因素。应用孟德尔随机化确定的缺血性卒中生物标志物共12个，其中凝血因子Ⅺ和载脂蛋白α是更具潜力的药物靶点且已有相关药物进入临床研究阶段。
结论缺血性卒中领域的孟德尔随机化研究主要在以英国为代表的欧洲国家、美国和中国开展。IL-6等炎症因素是主要研究热点，且相关研究为凝血因子Ⅺ和载脂蛋白α等生物标志物作为药物靶点提供证据。

文章导读：

本研究通过CiteSpace对缺血性卒中领域的孟德尔随机化研究进行文献计量学与可视化分析，发现以英国和美国为研究中心，以IL-6为代表的炎症因素为研究热点。查询相关生物标志物的药物研发情况，发现有以凝血因子Ⅺ和载脂蛋白α为靶点的药物研究进入临床阶段。

关键词: 缺血性卒中; 孟德尔随机化分析; 文献计量学; 可视化分析; 生物标志物

Abstract: Objective To investigate the current status and hotspots of Mendelian randomization (MR) studies in the field of ischemic stroke (IS), and to provide reference for future research directions, digging directions of drug targets and exploring mechanism.
Methods The MR related English literature in the field of IS in the Web of Science Core Collection was retrieved up to September 2022. CiteSpace was used for cooperation network analysis among countries, institutions and authors, co-citation analysis of literature, co-occurrence and cluster analysis of keywords. Drug development of biomarkers casually linked to IS was inquired by the PharmSnap Global New Drug Database.
Results A total of 200 articles were retrieved, and these studies entered a stage of rapid development in 2018. England had 80 articles, with intermediary centrality of 0.37 and 27 cooperation countries, while the US had 63 articles, with intermediary centrality of 0.10 and 21 cooperation countries or territories. All of the above data were in the top three of all countries or territories, making England and the US research centers in this area. China has published 106 articles, only with 16 cooperation countries or territories. Rainer Malik from Germany had published 20 papers, with 552 citation and 25 co-authors, all ranking the first. IL-6 was the only biological factor defined as a cluster label in the keywords clustering graph, and “inflammation” was the second most studied risk factor for IS in the keywords co-occurrence graph in the last three years. Among the 12 biomarkers of IS identified by MR, coagulation factor Ⅺ and lipoprotein (a) were the more promising drug targets and relevant drugs have entered clinical trials phase.
Conclusions MR studies in the field of IS were carried out mainly in European countries or territories represented by England, the US and China. Inflammatory factors such as IL-6 were major research hotspots, and related studies provided evidence for biomarkers, such as coagulation factor Ⅺ and lipoprotein (a), as drug targets.

Key words: Ischemic stroke; Mendelian randomization analysis; Bibliometrics; Visual analysis; Biomarker

李兰欣, 许喆, 勾岚, 石延枫, 刘阳, 赵曼曼, 李昊, 程丝. 缺血性卒中领域孟德尔随机化研究的文献计量学与可视化分析[J]. 中国卒中杂志, 2023, 18(03): 273-280.

LI Lanxin, XU Zhe, GOU Lan, SHI Yanfeng, LIU Yang, ZHAO Manman, LI Hao, CHENG Si.

The Bibliometrics and Visual Analysis of Mendelian Randomization Studies in Ischemic Stroke

[J]. Chinese Journal of Stroke, 2023, 18(03): 273-280.

参考文献

[1] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2020（中文版）（1）[J]. 中国卒中杂志，2022，17（5）：433-447.
[2] MALIK R，CHAUHAN G，TRAYLOR M，et al. Multiancestry genome-wide association study of 520，000 subjects identifies 32 loci associated with stroke and stroke subtypes[J]. Nat Genet，2018，50（4）：524-537.
[3] HEMANI G，ZHENG J，ELSWORTH B，et al. The MR-base platform supports systematic causal inference across the human phenome[J/OL]. eLife，2018，7：e34408[2022-11-19]. https://doi.org/10.7554/eLife.34408.
[4] VERBANCK M，CHEN C Y，NEALE B，et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J]. Nat Genet，2018，50（5）：693-698.
[5] YUAN S，CARTER P，MASON A M，et al. Genetic liability to rheumatoid arthritis in relation to coronary artery disease and stroke risk[J]. Arthritis Rheumatol，2022，74（10）：1638-1647.
[6] GAO N，KONG M J，LI X B，et al. Systemic lupus erythematosus and cardiovascular disease：a Mendelian randomization study[J/OL]. Front Immunol，2022，13：908831[2022-11-19]. https://doi.org/10.3389/fimmu.2022. 908831.
[7] CHEN H，ZHUO C G，ZHENG L R. Assessing causal associations of atopic dermatitis with heart failure and other cardiovascular outcomes：a Mendelian randomization study[J/OL]. Front Cardiovasc Med，2022，9：868850[2022-11-19]. https://doi.org/10. 3389/fcvm.2022.868850.
[8] YUAN S，LIN A，HE Q Q，et al. Circulating interleukins in relation to coronary artery disease，atrial fibrillation and ischemic stroke and its subtypes：a two-sample Mendelian randomization study[J/OL]. Int J Cardiol，2020，313：99-104[2022-11-19]. https://doi.org/10.1016/j.ijcard. 2020.03.053.
[9] GEORGAKIS M K，PARODI L，FRERICH S，et al. Genetic architecture of stroke of undetermined source：overlap with known stroke etiologies and associations with modifiable risk factors[J]. Ann Neurol，2022，91（5）：640-651.
[10] GEORGAKIS M K，MALIK R，GILL D，et al. Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes：a Mendelian randomization study[J/OL]. Circ Genom Precis Med，2020，13（3）：e002872[2022-11-19]. https://doi.org/10.1161/CIRCGEN.119. 002872.
[11] CUPIDO A J，ASSELBERGS F W，NATARAJAN P，et al. Dissecting the IL-6 pathway in cardiometabolic disease：a Mendelian randomization study on both IL6 and IL6R[J]. Br J Clin Pharmacol，2022，88（6）：2875-2884.
[12] LIN J X，WANG Y L，WANG Y J，et al. Inflammatory biomarkers and risk of ischemic stroke and subtypes：a 2-sample Mendelian randomization study[J]. Neurol Res，2020，42（2）：118-125.
[13] EMDIN C A，KHERA A V，NATARAJAN P，et al. Phenotypic characterization of genetically lowered human lipoprotein（a）levels[J]. J Am Coll Cardiol，2016，68（25）：2761-2772.
[14] LEE S，KIM O J，LEE K O，et al. Enhancing the therapeutic potential of CCL2-overexpressing mesenchymal stem cells in acute stroke[J/OL]. Int J Mol Sci，2020，21（20）：7795[2022-11-19]. https://doi.org/10.3390/ijms21207795.

[1]	程忻, 董强. 急性缺血性卒中再灌注治疗的新选择[J]. 中国卒中杂志, 2023, 18(03): 245-246.
[2]	吴川杰, 吉训明. ANGEL-ASPECT：大梗死核心急性缺血性卒中血管内治疗的中国方案[J]. 中国卒中杂志, 2023, 18(03): 247-249.
[3]	许喆, 程丝, 刘阳, 石延枫, 孟霞, 姜勇, 李昊. 基因组时代卒中遗传学研究的文献计量学及可视化分析[J]. 中国卒中杂志, 2023, 18(03): 254-265.
[4]	勾岚, 许喆, 李兰欣, 石延枫, 刘阳, 赵曼曼, 李昊, 程丝. 基于文献计量学分析缺血性脑血管病预后的基因组学研究[J]. 中国卒中杂志, 2023, 18(03): 266-272.
[5]	陈悦薇, 徐群. 脑小血管病的外周标志物及其多组学研究进展[J]. 中国卒中杂志, 2023, 18(03): 340-346.
[6]	王文洁, 吕书玉, 侯叶叶, 毛佳文, 韩颖, 李子孝. 缺血性脑血管病：回眸2022[J]. 中国卒中杂志, 2023, 18(02): 123-132.
[7]	霍晓川, 孙大鹏, 贾白雪, 高峰, 马宁, 莫大鹏, 缪中荣. 神经介入：回眸2022[J]. 中国卒中杂志, 2023, 18(02): 133-144.
[8]	宗黎霞, 王献伟, 李子孝, 赵性泉, 刘丽萍, 李昊, 孟霞, 王伊龙, 王拥军. 血清丙氨酸转氨酶与急性缺血性脑血管病临床结局的相关性研究[J]. 中国卒中杂志, 2023, 18(02): 185-193.
[9]	张英, 柴云花, 张建霞, 刘俐君, 安俊红. 国内外卒中患者照顾者领域研究热点与前沿可视化分析[J]. 中国卒中杂志, 2023, 18(02): 213-220.
[10]	沈懿, 武剑. 缺血性卒中二级预防降压药物的选择[J]. 中国卒中杂志, 2023, 18(01): 54-59.
[11]	宋晓微, 桑振华, 侯朵朵, 陈文文, 张红亮, 郑卓肇, 赵锡海, 李睿, 武剑. 血压昼夜节律变化与颅内动脉粥样硬化斑块特征的相关性研究[J]. 中国卒中杂志, 2023, 18(01): 61-67.
[12]	吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371.
[13]	蒋林, 李靖. 基于知识图谱分析人工智能用于卒中研究的现状及趋势 [J]. 中国卒中杂志, 2022, 17(12): 1372-1380.
[14]	伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170.
[15]	王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177.